Research location
Trélazé
France
Advertisement
Research activity in Trélazé
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 11 trials and 11 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Trélazé
11 linked trials · page 1 of 1Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart FailureNCT06427304 · 2024-07-01 · 1 site observation
RECRUITING
Safety and Performance Assessment of Drug-Eluting Stent CRE8 in Diabetic PatientsNCT03842813 · 2019-04-09 · 1 site observation
UNKNOWN
Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU ProgramNCT02933346 · 2016-09-01 · 1 site observation
COMPLETED
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive PatientsNCT01042392 · 2009-11-01 · 1 site observation
COMPLETED
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational StudyNCT00909038 · 2009-05-01 · 1 site observation
COMPLETED
National Survey on Hypertension in General Practitioner (GP) ConsultationNCT00695656 · 2008-04-01 · 1 site observation
COMPLETED
National Survey on Hypertension in Cardiologic Private PracticeNCT00695175 · 2008-02-01 · 1 site observation
COMPLETED
Tysabri Observational ProgramNCT00493298 · 2007-06-29 · 1 site observation
COMPLETED
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)NCT00313209 · 2006-04-01 · 1 site observation
COMPLETED
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifNCT00317941 · 2006-03-01 · 1 site observation
COMPLETED
GALLANT 22 Tesaglitazar vs. PlaceboNCT00252837 · 2005-04-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.